Evaluating the supportive care costs of severe radiochemotherapy-lnduced mucositis and pharyngitis results from a northwestern university costs of cancer program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a veterans administration hospital, or a comprehensive cancer care center

Narissa J. Nonzee, Neal A. Dandade, Talar Markossian, Mark Agulnik, Athanassios Argiris, Jyoti D. Patel, Robert C. Kern, Hidayatullah G. Munshi, BElizabeth A. Calhoupr, Charles L. BennettJi

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

BACKGROUND. Few studies have examined the costs of supportive care for radiochemotherapy-induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite the documented negative clinical impact of these complications. METHODS. The authors identified a retrospective cohort of patients with HNC or nonsmall lung cancer (NSCLC) who had received radiochemotherapy at 1 of 3 Chicago hospitals (a Veterans Administration hospital, a county hospital, or a tertiary care hospital). Charts were reviewed for the presence/absence of severe mucositis/pharyngitis and the medical resources that were used. Resource estimates were converted into cost units obtained from standard sources (hospital bills, Medicare physician fee schedule, Red Book). Estimates of resources used and direct medical costs were compared for patients who did and patients who did not develop severe mucositis/pharyngitis. RESULTS. Severe mucositis/pharyngitis occurred in 70.1% of 99 patients with HNC and in 37.5% of 40 patients with NSCLC during radiochemotherapy. The total median medical costs per patient were 7dollar;39,313 for patients with mucositis/pharyngitis and $20,798 for patients without mucositis/pharyngitis (P = .007). Extended inpatient hospitalization accounted for $12,600 of the increased medical costs (median 14 days [$19,600] with severe mucositis/pharyngitis vs 5 days [$7000] without; P = .017). For patients who had HNC with mucositis/pharyngitis, incremental inpatient hospitalization costs were $14,000, and total medical costs were dollar;17,244. For patients who had NSCLC with mucositis/pharyngitis, these costs were $11,200 and $$25,000, respectively. CONCLUSIONS. In the current study, the medical costs among the patients with HNC and NSCLC who received radiochemotherapy were greater for those who

Original languageEnglish (US)
Pages (from-to)1446-1452
Number of pages7
JournalCancer
Volume113
Issue number6
DOIs
StatePublished - Sep 15 2008
Externally publishedYes

Fingerprint

Veterans Hospitals
County Hospitals
United States Department of Veterans Affairs
Mucositis
Pharyngitis
Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Neck
Head
Costs and Cost Analysis
Head and Neck Neoplasms
Neoplasms
Lung Neoplasms
Inpatients
Hospitalization
Fee Schedules
Tertiary Healthcare
Medicare
Tertiary Care Centers

Keywords

  • Cost analysis
  • Head and neck
  • Mucositis
  • Pharyngitis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluating the supportive care costs of severe radiochemotherapy-lnduced mucositis and pharyngitis results from a northwestern university costs of cancer program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a veterans administration hospital, or a comprehensive cancer care center. / Nonzee, Narissa J.; Dandade, Neal A.; Markossian, Talar; Agulnik, Mark; Argiris, Athanassios; Patel, Jyoti D.; Kern, Robert C.; Munshi, Hidayatullah G.; Calhoupr, BElizabeth A.; BennettJi, Charles L.

In: Cancer, Vol. 113, No. 6, 15.09.2008, p. 1446-1452.

Research output: Contribution to journalArticle

Nonzee, Narissa J. ; Dandade, Neal A. ; Markossian, Talar ; Agulnik, Mark ; Argiris, Athanassios ; Patel, Jyoti D. ; Kern, Robert C. ; Munshi, Hidayatullah G. ; Calhoupr, BElizabeth A. ; BennettJi, Charles L. / Evaluating the supportive care costs of severe radiochemotherapy-lnduced mucositis and pharyngitis results from a northwestern university costs of cancer program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a veterans administration hospital, or a comprehensive cancer care center. In: Cancer. 2008 ; Vol. 113, No. 6. pp. 1446-1452.
@article{6c73013cf5e24549b6738682cfe35e28,
title = "Evaluating the supportive care costs of severe radiochemotherapy-lnduced mucositis and pharyngitis results from a northwestern university costs of cancer program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a veterans administration hospital, or a comprehensive cancer care center",
abstract = "BACKGROUND. Few studies have examined the costs of supportive care for radiochemotherapy-induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite the documented negative clinical impact of these complications. METHODS. The authors identified a retrospective cohort of patients with HNC or nonsmall lung cancer (NSCLC) who had received radiochemotherapy at 1 of 3 Chicago hospitals (a Veterans Administration hospital, a county hospital, or a tertiary care hospital). Charts were reviewed for the presence/absence of severe mucositis/pharyngitis and the medical resources that were used. Resource estimates were converted into cost units obtained from standard sources (hospital bills, Medicare physician fee schedule, Red Book). Estimates of resources used and direct medical costs were compared for patients who did and patients who did not develop severe mucositis/pharyngitis. RESULTS. Severe mucositis/pharyngitis occurred in 70.1{\%} of 99 patients with HNC and in 37.5{\%} of 40 patients with NSCLC during radiochemotherapy. The total median medical costs per patient were 7dollar;39,313 for patients with mucositis/pharyngitis and $20,798 for patients without mucositis/pharyngitis (P = .007). Extended inpatient hospitalization accounted for $12,600 of the increased medical costs (median 14 days [$19,600] with severe mucositis/pharyngitis vs 5 days [$7000] without; P = .017). For patients who had HNC with mucositis/pharyngitis, incremental inpatient hospitalization costs were $14,000, and total medical costs were dollar;17,244. For patients who had NSCLC with mucositis/pharyngitis, these costs were $11,200 and $$25,000, respectively. CONCLUSIONS. In the current study, the medical costs among the patients with HNC and NSCLC who received radiochemotherapy were greater for those who",
keywords = "Cost analysis, Head and neck, Mucositis, Pharyngitis",
author = "Nonzee, {Narissa J.} and Dandade, {Neal A.} and Talar Markossian and Mark Agulnik and Athanassios Argiris and Patel, {Jyoti D.} and Kern, {Robert C.} and Munshi, {Hidayatullah G.} and Calhoupr, {BElizabeth A.} and BennettJi, {Charles L.}",
year = "2008",
month = "9",
day = "15",
doi = "10.1002/cncr.23714",
language = "English (US)",
volume = "113",
pages = "1446--1452",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Evaluating the supportive care costs of severe radiochemotherapy-lnduced mucositis and pharyngitis results from a northwestern university costs of cancer program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a veterans administration hospital, or a comprehensive cancer care center

AU - Nonzee, Narissa J.

AU - Dandade, Neal A.

AU - Markossian, Talar

AU - Agulnik, Mark

AU - Argiris, Athanassios

AU - Patel, Jyoti D.

AU - Kern, Robert C.

AU - Munshi, Hidayatullah G.

AU - Calhoupr, BElizabeth A.

AU - BennettJi, Charles L.

PY - 2008/9/15

Y1 - 2008/9/15

N2 - BACKGROUND. Few studies have examined the costs of supportive care for radiochemotherapy-induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite the documented negative clinical impact of these complications. METHODS. The authors identified a retrospective cohort of patients with HNC or nonsmall lung cancer (NSCLC) who had received radiochemotherapy at 1 of 3 Chicago hospitals (a Veterans Administration hospital, a county hospital, or a tertiary care hospital). Charts were reviewed for the presence/absence of severe mucositis/pharyngitis and the medical resources that were used. Resource estimates were converted into cost units obtained from standard sources (hospital bills, Medicare physician fee schedule, Red Book). Estimates of resources used and direct medical costs were compared for patients who did and patients who did not develop severe mucositis/pharyngitis. RESULTS. Severe mucositis/pharyngitis occurred in 70.1% of 99 patients with HNC and in 37.5% of 40 patients with NSCLC during radiochemotherapy. The total median medical costs per patient were 7dollar;39,313 for patients with mucositis/pharyngitis and $20,798 for patients without mucositis/pharyngitis (P = .007). Extended inpatient hospitalization accounted for $12,600 of the increased medical costs (median 14 days [$19,600] with severe mucositis/pharyngitis vs 5 days [$7000] without; P = .017). For patients who had HNC with mucositis/pharyngitis, incremental inpatient hospitalization costs were $14,000, and total medical costs were dollar;17,244. For patients who had NSCLC with mucositis/pharyngitis, these costs were $11,200 and $$25,000, respectively. CONCLUSIONS. In the current study, the medical costs among the patients with HNC and NSCLC who received radiochemotherapy were greater for those who

AB - BACKGROUND. Few studies have examined the costs of supportive care for radiochemotherapy-induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite the documented negative clinical impact of these complications. METHODS. The authors identified a retrospective cohort of patients with HNC or nonsmall lung cancer (NSCLC) who had received radiochemotherapy at 1 of 3 Chicago hospitals (a Veterans Administration hospital, a county hospital, or a tertiary care hospital). Charts were reviewed for the presence/absence of severe mucositis/pharyngitis and the medical resources that were used. Resource estimates were converted into cost units obtained from standard sources (hospital bills, Medicare physician fee schedule, Red Book). Estimates of resources used and direct medical costs were compared for patients who did and patients who did not develop severe mucositis/pharyngitis. RESULTS. Severe mucositis/pharyngitis occurred in 70.1% of 99 patients with HNC and in 37.5% of 40 patients with NSCLC during radiochemotherapy. The total median medical costs per patient were 7dollar;39,313 for patients with mucositis/pharyngitis and $20,798 for patients without mucositis/pharyngitis (P = .007). Extended inpatient hospitalization accounted for $12,600 of the increased medical costs (median 14 days [$19,600] with severe mucositis/pharyngitis vs 5 days [$7000] without; P = .017). For patients who had HNC with mucositis/pharyngitis, incremental inpatient hospitalization costs were $14,000, and total medical costs were dollar;17,244. For patients who had NSCLC with mucositis/pharyngitis, these costs were $11,200 and $$25,000, respectively. CONCLUSIONS. In the current study, the medical costs among the patients with HNC and NSCLC who received radiochemotherapy were greater for those who

KW - Cost analysis

KW - Head and neck

KW - Mucositis

KW - Pharyngitis

UR - http://www.scopus.com/inward/record.url?scp=53149084484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53149084484&partnerID=8YFLogxK

U2 - 10.1002/cncr.23714

DO - 10.1002/cncr.23714

M3 - Article

C2 - 18683883

AN - SCOPUS:53149084484

VL - 113

SP - 1446

EP - 1452

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -